New kidney cancer drug therapy recommended for use in Canada.

Banner - Home page

Kidney Cancer Canada – Cancer du rein Canada welcomes the decision of the
pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) to recommend reimbursement of cabozantinib (Cabometyx) in patients with advanced renal cell carcinoma (RCC) who have received at least one prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy only if the following condition is met:

  • Cost-effectiveness is improved to an acceptable level.
    (Kidney Cancer Canada : that an acceptaple price is negociated)

If the condition cannot be met, pERC does not recommend reimbursement of cabozantinib. Reimbursement should be for patients who have been previously treated with at least one prior VEGFR TKI and treatment should continue until clinically meaningful disease progression or unacceptable toxicity.

The role of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) is to assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to the provinces and territories to help guide their drug funding decisions.

“We are happy to see pERC recognizes the need for more treatment options for patients,” says Stephen Andrew, Executive Director. “We urge the manufacturer and governments to move quickly to make this therapy available throughout Canada.”

Whatever happens, Canadian kidney cancer patients who currently access cabozantinib through a patient support program will remain on the therapy.

For more information contact Kidney Cancer Canada – Cancer du rein Canada at info@kidneycancercanada.ca or toll free at 1-866-598-7166

Kidney Cancer Canada